5 CONCLUSIONS
Our study confirms that HDM SLIT-tablet (ACARIZAX®) is a safe and well-tolerated treatment for HDM AR in daily clinical practice.
Adverse events are common but are mostly mild and decrease during the first year. Clinical scores (CARAT) improve, and symptomatic medication use decreases with treatment duration. If patients continue therapy, compliance rates are high and treatment satisfaction is good. However, with a stopping rate of 14.5% and 18.3% due to adverse events and motivational reasons, compliance remains the main concern when starting HDM SLIT-tablet.